Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Canada OKs marketing of STAAR Surgical TICL
Monrovia, CA—STAAR Surgical Co. has received approval from the Canadian Therapeutic Products Directorate to market its Visian Toric lens (TICL) in Canada.
Monrovia, CA-STAAR Surgical Co. has received approval from the Canadian Therapeutic Products Directorate to market its Visian Toric lens (TICL) in Canada. The posterior chamber phakic IOL corrects myopia and astigmatism without tissue removal, according to the company.
The Korean Food and Drug Administration, of South Korea, gave its approval to market the lens May 19.
Related Videos
Related Content
